What stability advantage did the Extracellular Vesicle (EV) platform promise over frozen mRNA vaccines?

Greater stability at higher, less demanding temperatures

Researchers, including those from Harvard University and the University of Nebraska–Lincoln, are exploring next-generation solutions to mitigate the extreme logistical hurdles presented by ultra-cold chains. Their work on the Extracellular Vesicle (EV)-based vaccine platform repurposes natural nanoscopic cargo transports found within the body, which use a lipid bilayer structure. Early testing indicated that this approach not only induced high antibody production but also offered the significant potential benefit of greater physical stability, suggesting viability at temperatures substantially higher and far less demanding than the frozen conditions required for current Lipid Nanoparticle (LNP)-based mRNA vaccines.